for-phone-onlyfor-tablet-portrait-upfor-tablet-landscape-upfor-desktop-upfor-wide-desktop-up

Benitec Biopharma Ltd

BNTC.OQ

Latest Trade

0.62USD

Change

--(--)

Today's Range

--

 - 

--

52 Week Range

0.56

 - 

2.65

As of on the Australian Stock Exchange Ltd ∙ Minimum 15 minute delay

Pricing

Previous Close
0.62
Open
--
Volume
--
3M AVG Volume
11.67
Today's High
--
Today's Low
--
52 Week High
2.65
52 Week Low
0.56
Shares Out (MIL)
257.03
Market Cap (MIL)
15.34
Forward P/E
--
Dividend (Yield %)
--

Latest Developments

More

Benitec Biopharma Enters Agreement To Issue 2.8 Mln American Depositary Shares

Benitec Biopharma Says In Q3 2019 Co Conducted A Workforce Reduction Of About 50%

Benitec Biopharma Receives Notice From Nasdaq

for-phone-onlyfor-tablet-portrait-upfor-tablet-landscape-upfor-desktop-upfor-wide-desktop-up

About Benitec Biopharma Ltd

Benitec Biopharma Limited is a biotechnology company. The Company is engaged in progressing programs through the clinic; the commercialization of its Intellectual Property (IP); development of its therapeutic pipeline and pre-clinical programs, and funding, and protecting and building the IP estate. Its In-house product candidates include TT-034, BB-HB-331, BB-AMD-211 and ddRNAi therapeutic. It is focused on commercialization by licensing and partnering of patents and licenses in biotechnology, in functional genomics, with applications in biomedical research and human therapeutics. It has a pipeline of in-house and partnered therapeutic programs based on its patented gene-silencing technology, deoxyribonucleic acid (DNA)-directed ribonucleic acid interference (ddRNAi). The Company is engaged in developing treatments for chronic human conditions, such as hepatitis B, wet age-related macular degeneration (AMD), and oculopharyngeal muscular dystrophy (OPMD) based on this technology.

Industry

Biotechnology & Drugs

Contact Info

Benitec Biopharma, L 14 114 William St

+61.3.86927222

https://benitec.com/

Executive Leadership

Jerel A. Banks

Executive Chairman of the Board

Gregory West

Chief Executive Officer, Company Secretary

Bryan Dulhunty

Chief Financial Officer

Michael Graham

Chief Scientific Officer

Oliver Kidd

Company Secretary

Key Stats

Price To Earnings (TTM)
3.16
Price To Sales (TTM)
0.92
Price To Book (MRQ)
0.53
Price To Cash Flow (TTM)
3.55
Total Debt To Equity (MRQ)
0.00
LT Debt To Equity (MRQ)
0.00
Return on Investment (TTM)
19.29
Return on Equity (TTM)
16.79

Latest News

Latest News

BRIEF-Benitec Biopharma Launches Entitlement Offer And Placement

* LAUNCHED ENTITLEMENT OFFER TO ELIGIBLE SHAREHOLDERS AND INSTITUTIONAL PLACEMENT TO HIGHBRIDGE CAPITAL MANAGEMENT LLC

BRIEF-Benitec Biopharma Seeks Trading Halt

* SEEKS TRADING HALT PENDING ANNOUNCEMENT REGARDING CAPITAL RAISING Source text for Eikon: Further company coverage:

BRIEF-Benitec Biopharma ‍Says U.S. FDA Granted Orphan Drug Designation To BB-301​

* U.S. FDA HAS GRANTED ORPHAN DRUG DESIGNATION TO BB-301 FOR TREATMENT OF OCULOPHARYNGEAL MUSCULAR DYSTROPHY(OPMD) Source text for Eikon: Further company coverage:

BRIEF-Benitec Biopharma Posts Qtrly ‍Loss Of A$2.9 mln

* QTRLY LOSS OF A$2.9 MILLION VERSUS PROFIT OF A$0.8 MILLION Source text for Eikon: Further company coverage:

BRIEF-Benitec Biopharma provides update On Opmd Orphan Disease program

* BENITEC BIOPHARMA PROVIDES UPDATE ON OPMD ORPHAN DISEASE PROGRAM

BRIEF-Benitec Biopharma says working with regulators to advance BB-301 into the clinic as quickly as possible

* Benitec Biopharma says its BB-301, represents clinical candidate that it intends to advance into human clinical trials in the second half of 2018

BRIEF-Benitec Biopharma says files for stock shelf offering of upto $20 mln

* Benitec Biopharma says files for stock shelf offering of upto $20 million - sec filing Source text (http://bit.ly/2rIk5RV) Further company coverage:

BRIEF-Benitec Biopharma says key pre-clinical data on muscular dystrophy published in nature communications

* Benitec Biopharma Ltd - key pre-clinical data on oculopharyngeal muscular dystrophy (opmd) published in nature communications

BRIEF-Benitec Biopharma initiates work on two oncology pipeline programs

* Initiated work on two new oncology pipeline programs after executing a research collaboration agreement with Nant Capital Llc Source text for Eikon: Further company coverage:

BRIEF-Benitec Biopharma gets orphan drug designation in EU for BB-301

* Receives orphan drug designation in European Union for BB-301 Source text for Eikon: Further company coverage:

Quote and financial data from Refinitiv. Fund performance data provided by Lipper. All quotes delayed a minimum of 15 minutes.

for-phone-onlyfor-tablet-portrait-upfor-tablet-landscape-upfor-desktop-upfor-wide-desktop-up